Abstract
There have been a number of highly publicized safety-based drug withdrawals in the United States in recent years. We conducted a review of drugs withdrawn since 1993 and examined trends in drug withdrawals. Our objective was to determine the frequency and characteristics of withdrawn drugs and trends since 1993, and to discuss the implications of the findings. We found that a mean of 1.5 drugs per year have been withdrawn since 1993, and that the number of withdrawals has not increased over time. However, some recent drug withdrawals have impacted large numbers of people. The rate of withdrawals alone is not an adequate measure of the status of drug safety in the US, and there is a serious dearth of data that can be used to examine the impact of drug withdrawals. Although drug withdrawals are an important issue to address, drug safety policies need to be developed within the broader context of drug safety and effectiveness. A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts.
Keywords: Prescription drug withdrawals, drug safety, evidence base, policy implications, pharmacoepidemiology, drug surveillance
Current Drug Safety
Title: Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Volume: 2 Issue: 3
Author(s): Amalia M. Issa, Kathryn A. Phillips, Stephanie Van Bebber, Hima G. Nidamarthy, Karen E. Lasser, Jennifer S. Haas, Brian K. Alldredge, Robert M. Wachter and David W. Bates
Affiliation:
Keywords: Prescription drug withdrawals, drug safety, evidence base, policy implications, pharmacoepidemiology, drug surveillance
Abstract: There have been a number of highly publicized safety-based drug withdrawals in the United States in recent years. We conducted a review of drugs withdrawn since 1993 and examined trends in drug withdrawals. Our objective was to determine the frequency and characteristics of withdrawn drugs and trends since 1993, and to discuss the implications of the findings. We found that a mean of 1.5 drugs per year have been withdrawn since 1993, and that the number of withdrawals has not increased over time. However, some recent drug withdrawals have impacted large numbers of people. The rate of withdrawals alone is not an adequate measure of the status of drug safety in the US, and there is a serious dearth of data that can be used to examine the impact of drug withdrawals. Although drug withdrawals are an important issue to address, drug safety policies need to be developed within the broader context of drug safety and effectiveness. A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts.
Export Options
About this article
Cite this article as:
Issa M. Amalia, Phillips A. Kathryn, Van Bebber Stephanie, Nidamarthy G. Hima, Lasser E. Karen, Haas S. Jennifer, Alldredge K. Brian, Wachter M. Robert and Bates W. David, Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668855
DOI https://dx.doi.org/10.2174/157488607781668855 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Readthrough of SCN5A Nonsense Mutations p.R1623X and p.S1812X Questions Gene-therapy in Brugada Syndrome
Current Gene Therapy Nanotechnology approaches for pain therapy through transdermal drug delivery
Current Pharmaceutical Design Targeting Calcium and the Mitochondria in Prevention of Pathology in the Heart
Current Drug Targets Antitumor Titanium Compounds
Mini-Reviews in Medicinal Chemistry The Biological Effects of Diagnostic Cardiac Imaging
Current Pharmaceutical Design Chaperones and Cardiac Misfolding Protein Diseases
Current Protein & Peptide Science Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Enkephalinase Inhibitors: Potential Agents for the Management of Pain
Current Drug Targets Racing of the Biological Pacemaker
Recent Patents on DNA & Gene Sequences Sudden Death Associated with Complex Treatment of Acute Mania: Case Report and Toxicological Findings
Current Psychopharmacology Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Editorial (Thematic Issue: Perspectives of Antiarrhythmic Therapy: New Trails, Challenges and Pitfalls)
Current Pharmaceutical Design Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Drug Therapy in Brugada Syndrome
Current Drug Targets - Cardiovascular & Hematological Disorders The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Efficacy and Cardiovascular Safety of Thiazolidinediones
Current Drug Safety